T1	Drug 45 52;7 26;71 102	product any investigational other than the study vaccine(s)
T2	Drug 30 52;7 10;71 102	non-registered product any other than the study vaccine(s)
*	OR T1 T2
T3	Drug 54 58	drug
T4	Drug 62 69	vaccine
*	OR T3 T4
T5	Scope 54 69	drug or vaccine
T6	Scope 7 52;71 102	any investigational or non-registered product other than the study vaccine(s)
R1	Subsumes Arg1:T6 Arg2:T5	
T7	Temporal 103 117	within 30 days
T8	Observation 164 175	planned use
T9	Temporal 176 199	during the study period
R2	Has_temporal Arg1:T8 Arg2:T9	
R3	Has_temporal Arg1:T6 Arg2:T7	
*	OR T6 T8
R4	Has_scope Arg1:T8 Arg2:T5	
T10	Drug 258 276	immunosuppressants
T11	Drug 280 308	other immune-modifying drugs
*	OR T10 T11
T12	Temporal 309 326	within six months
T13	Temporal 201 208	Chronic
T14	Temporal 236 253	more than 14 days
R5	Subsumes Arg1:T13 Arg2:T14	
T15	Scope 258 308	immunosuppressants or other immune-modifying drugs
R6	Has_temporal Arg1:T15 Arg2:T13	
R7	Has_temporal Arg1:T15 Arg2:T12	
T16	Observation 361 368	Planned
T17	Drug 405 412	vaccine
T18	Qualifier 413 447	not foreseen by the study protocol
R8	Has_qualifier Arg1:T17 Arg2:T18	
T19	Temporal 459 515	period starting one month before each dose of vaccine(s)
T20	Temporal 561 581	1 month after dose 3
T21	Temporal 520 557	ending 7 days after dose 1 and dose 2
T22	Drug 540 546	dose 1
T23	Drug 551 557	dose 2
T24	Drug 575 581	dose 3
*	OR T22 T23
T25	Scope 540 557	dose 1 and dose 2
T26	Scope 459 581	period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose 3
R10	Has_scope Arg1:T17 Arg2:T26	
R11	AND Arg1:T16 Arg2:T17	
T27	Drug 593 604	vaccination
T28	Condition 613 623	diphtheria
T29	Condition 625 632	tetanus
T30	Condition 634 643	pertussis
T31	Condition 645 650	polio
T32	Condition 652 663	hepatitis B
T33	Condition 665 694	Haemophilus influenzae type b
T34	Condition 703 716	S. pneumoniae
T35	Temporal 782 816	within the first two weeks of life
T36	Qualifier 758 781	first dose can be given
R12	Has_temporal Arg1:T36 Arg2:T35	
*	OR T28 T29 T30 T31 T32 T33 T34
T37	Scope 613 716	diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae
R13	Has_scope Arg1:T27 Arg2:T37	
T38	Scope 593 716	vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae
T39	Drug 739 747	vaccines
R14	Has_qualifier Arg1:T39 Arg2:T36	
T40	Observation 860 867	History
T41	Condition 887 897	diphtheria
T42	Condition 899 906	tetanus
T43	Condition 908 917	pertussis
T44	Condition 919 930	hepatitis B
T45	Condition 932 937	polio
T46	Condition 943 972	Haemophilus influenzae type b
*	OR T45 T46 T44 T43 T42 T41
T47	Scope 887 972	diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b
R16	Has_scope Arg1:T40 Arg2:T47	
T48	Condition 995 1011	allergic disease
T49	Observation 984 991	History
T50	Condition 1015 1024;995 1003	reactions allergic
T51	Scope 995 1024	allergic disease or reactions
*	OR T50 T48
R17	Has_scope Arg1:T49 Arg2:T51	
T52	Qualifier 1038 1049	exacerbated
R18	Has_qualifier Arg1:T51 Arg2:T52	
T53	Condition 1096 1104	seizures
T54	Observation 1085 1092	History
T55	Condition 1185 1203	febrile convulsion
T56	Qualifier 1171 1184	uncomplicated
T57	Multiplier 1163 1169	single
T59	Condition 1220 1240	neurological disease
T60	Condition 1243 1256	Acute disease
T61	Temporal 1257 1281	at the time of enrolment
R22	Has_temporal Arg1:T60 Arg2:T61	
T62	Condition 1310 1327;1347 1356	immunosuppressive condition
T63	Condition 1331 1356	immunodeficient condition
*	OR T62 T63
T64	Observation 1398 1412	family history
T65	Condition 1416 1426;1441 1457	congenital immunodeficiency
T66	Condition 1430 1457	hereditary immunodeficiency
T67	Scope 1416 1457	congenital or hereditary immunodeficiency
R23	Has_scope Arg1:T64 Arg2:T67	
T68	Condition 1460 1484	Major congenital defects
T69	Condition 1488 1511	serious chronic illness
*	OR T68 T69
T70	Drug 1532 1547	immunoglobulins
T71	Drug 1555 1573	any blood products
*	OR T70 T71
T72	Temporal 1574 1585	since birth
T73	Scope 1532 1573	immunoglobulins and/or any blood products
T74	Observation 1589 1596	planned
T75	Temporal 1612 1648	during the active phase of the study
R25	Has_temporal Arg1:T74 Arg2:T75	
*	OR T72 T74
T76	Scope 1574 1648	since birth or planned administration during the active phase of the study
R24	Has_scope Arg1:T73 Arg2:T76	
T77	Negation 717 738	with the exception of
R15	Has_negation Arg1:T39 Arg2:T77	
R26	AND Arg1:T38 Arg2:T39	
T78	Reference_point 789 816	the first two weeks of life
R27	Has_index Arg1:T35 Arg2:T78	
R19	Has_qualifier Arg1:T55 Arg2:T56	
R20	Has_multiplier Arg1:T55 Arg2:T57	
T58	Negation 1121 1135	does not apply
R21	Has_negation Arg1:T55 Arg2:T58	
R28	AND Arg1:T53 Arg2:T55	
*	OR T53 T59
T79	Scope 1096 1240	seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or neurological disease
R29	Has_temporal Arg1:T79 Arg2:T54	
T80	Reference_point 1272 1281	enrolment
R30	Has_index Arg1:T61 Arg2:T80	
T81	Reference_point 1623 1648	active phase of the study
R31	Has_index Arg1:T75 Arg2:T81	
T82	Reference_point 1580 1585	birth
R32	Has_index Arg1:T72 Arg2:T82	
T83	Reference_point 492 515	each dose of vaccine(s)
R33	Has_index Arg1:T19 Arg2:T83	
T84	Reference_point 540 557	dose 1 and dose 2
R34	Has_index Arg1:T21 Arg2:T84	
T85	Reference_point 575 581	dose 3
R35	Has_index Arg1:T20 Arg2:T85	
R9	multi Arg1:T85 Arg2:T24	
R36	multi Arg1:T84 Arg2:T25	
*	OR T21 T20
